Literature DB >> 11092206

Assessment of damage and activity in systemic sclerosis.

T A Medsger1.   

Abstract

The determination of damage and activity in the course of a disease are important matters. Monitoring damage activity is critical in the evaluation of individual patients and in evaluating treatment efficacy in clinical trials. A disease damage (severity) scale has been published for systemic sclerosis. A number of potential cytokine and other soluble protein markers of disease activity for this disease have been proposed in recent publications, reviewed here.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092206     DOI: 10.1097/00002281-200011000-00012

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  9 in total

Review 1.  Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.

Authors:  Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

2.  Alpha4beta1 and alpha4beta7 CD4 T cell numbers increase and CLA CD4 T cell numbers decrease in systemic sclerosis.

Authors:  E Scala; R Paganelli; F Sampogna; D Abeni; L Colonna; O De Pità; P Puddu; G Russo
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  Predictors of early mortality in systemic sclerosis: a case-control study comparing early versus late mortality in systemic sclerosis.

Authors:  Chris T Derk; Gonzalo Huaman; Jayne Littlejohn; Franklin Otieno; Sergio Jimenez
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

4.  The challenges and controversies of measuring disease activity in systemic sclerosis.

Authors:  Laura Ross; Murray Baron; Mandana Nikpour
Journal:  J Scleroderma Relat Disord       Date:  2018-03-27

5.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

6.  Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters.

Authors:  Luigi Caserta; Laura de Magistris; Mario Secondulfo; Giancarlo Caravelli; Gabriele Riegler; Giovanna Cuomo; Salvatore D'Angelo; Caterina Naclerio; Gabriele Valentini; Romano Carratù
Journal:  Rheumatol Int       Date:  2003-02-15       Impact factor: 2.631

7.  Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III.

Authors:  Murray Baron; Marie Hudson; Solène Tatibouet; Russell Steele; Ernest Lo; Sabrina Gravel; Geneviève Gyger; Tarek El Sayegh; Janet Pope; Audrey Fontaine; Ariel Masetto; Debora Matthews; Evelyn Sutton; Norman Thie; Niall Jones; Maria Copete; Dean Kolbinson; Janet Markland; Getulio Nogueira; David Robinson; Marvin Fritzler; Mervyn Gornitsky
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

8.  Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement.

Authors:  E Scala; S Pallotta; A Frezzolini; D Abeni; C Barbieri; F Sampogna; O De Pità; P Puddu; R Paganelli; G Russo
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

9.  Preliminary study of cardiovascular manifestations and cardiac severity scale in 58 patients with systemic sclerosis in iran using the medsger scale.

Authors:  Hadi Poormoghim; Mohamad Ali Poorkarim; Maziar Moradi Lakeh; Behnaz Nozary Heshmati; Simin Almasi; Mojtaba Hakim
Journal:  J Tehran Heart Cent       Date:  2010-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.